
Press Release

Stockholm, Sweden, June 1, 2022

Immunicum to Participate in Upcoming Conferences

Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced its participation in the following upcoming conferences:

Redeye Growth Day 2022

June 2, 2022

Immunicum CEO Erik Manting will participate in an on-site Q&A session on June 2, at 08:55 am CET. Further details including the on-demand corporate presentation are available via:

<https://redeye.ifairs.com/#/booth?id=687>

BioStock Life Science Spring Summit

June 8-9, 2022

Immunicum CEO Erik Manting will present on June 9, at 10:20 am CET.

<https://www.biostock.se/en/2022/04/biostock-life-science-spring-summit-june-8-9/>

European Hematology Association (EHA) 2022 Congress

June 9-17, 2022

<https://ehaweb.org/congress/eha2022-hybrid/eha2022-congress/>

BIO International Convention

June 13-16, 2022

<https://www.bio.org/events/bio-international-convention>

FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting
Chief Executive Officer
E-mail: ir@immunicum.com

INVESTOR RELATIONS

Julie Seidel
Stern Investor Relations
Telefon: +1 212-362-1200
E-mail: julie.seidel@sternir.com

MEDIA RELATIONS

Mario Brkulj
Valency Communications
Telephone: +49 160 9352 9951
E-mail: mbrkulj@valencycomms.eu

ABOUT IMMUNICUM AB (PUBL)

Immunicum is a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, two key challenges in oncology. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based therapies for blood-borne and solid tumors. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com